Genmab grows up: Celebrating 25 years, CEO prepares to wield 'pretty good buying power'

Twenty-five years after launching, Genmab co-founder and CEO Jan van de Winkel, Ph.D., has earned himself the right to briefly bask in the company’s success.

With eight approved therapies incorporating Genmab’s antibody tech, revenue is soaring, tripling since 2019 and up 13.5% year over year in 2023, according to an annual report. Meanwhile, the company’s cash on hand has quadrupled since 2019, and R&D investments are soaring.